Follow
IRLAB Therapeutics AB
Nasdaq First North Sweden (Sweden)
IRLAB Therapeutics AB is a Swedish based drug discovery and development company providing novel treatments for disorders of the brain. The company focusses on the innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's di IRLAB Therapeutics AB is a Swedish based drug discovery and development company providing novel treatments for disorders of the brain. The company focusses on the innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease.

Read more

Sector:
HEALTH CARE
Sector:
TECHNOLOGY
Media
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
IRLAB A
SE0012675361
Nasdaq First North Sweden
Sweden (SE)
Details of share in IRLAB Therapeutics AB with ticker IRLAB A
Status
Active
Order book id
Amount of instruments
43 029 919
Par value
0.1000
Market cap
Currency
SEK
Segment
First North Premier
First trading date
28 Feb 2017
Terms
Type
Price
Pre-money valuation
Time
IPO
60.00 SEK
304.2M SEK
30 Jan - 10 Feb 2017
IPO in IRLAB Therapeutics AB
Former ISIN
SE0009242225
Market
Nasdaq First North Sweden
Subscription period
30 Jan - 10 Feb 2017
Subscription price
Price per share
60.00 SEK
Target to raise
115 800 000 SEK
Types
Pre-money valuation
304 200 000 SEK
Subscription block size
Minimum subscription
100
Record date
Offer status
Closed
Listing status
Listed
First trading date
28 Feb 2017
Issue terms
The offer is aimed at the general public in Sweden and for professional investors in Sweden and internationally.
Type
Price
Pre-money valuation
Time
New issue
126.00 SEK
23 May - 23 May 2018
Share issue in IRLAB Therapeutics AB
Former ISIN
SE0009242225
Market
Nasdaq First North Sweden
Subscription period
23 May - 23 May 2018
Subscription price
Price per share
126.00 SEK
Target to raise
13 860 000 SEK
Types
Share issue
Pre-money valuation
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
Directed to US New Leaf Venture Partners, Second AP Fund, Third AP Fund, Fourth AP Fund, Handelsbanken Fonder AB and Thomas Olausson, Sven Sandberg and Alfred Berg Kapitalförvaltning AB.
Type
Price
Pre-money valuation
Time
New issue
27.00 SEK
12 Dec 2019
Share issue in IRLAB Therapeutics AB
Market
Nasdaq First North Sweden
Subscription date
12 Dec 2019
Subscription price
Price per share
27.00 SEK
Target to raise
70 500 000 SEK
Types
Share issue
Pre-money valuation
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
Directed issue through an accelerated bookbuilding procedure organized by Carnegie Investment Bank and Zonda Partners. The has been subscribed by, among others, Handelsbanken Fonder, the Fourth AP Fund, the Union, the Third AP Fund, and the Second AP Fund.
Comments for offer & related information
Amount of shares in issue 2 610 000.
This directed issue of approximately SEK 70.5 million was initiated after the market's closing on December 12, and should be completed before the market opens on December 13, 2019. In addition to this targeted issue, the company will also make a rights issue during the first quarter of 2020.
Type
Price
Pre-money valuation
Time
New issue
27.00 SEK
11 Feb - 25 Feb 2020
Share issue in IRLAB Therapeutics AB
Market
Nasdaq First North Sweden
Subscription period
11 Feb - 25 Feb 2020
Subscription price
27.00 SEK
Price per share
27.00 SEK
Target to raise
145 500 000 SEK
Types
Share issue
Pre-money valuation
Subscription block size
Minimum subscription
Record date
07 Feb 2020
Offer status
Closed
Listing status
Listed
Issue terms
Preference right 1:8. The company's shareholders have preferential rights to subscribe for Class A shares in the Rights Issue, whereby eight (8) existing shares (regardless of class of shares) entitle to subscribe for one (1) new class A shares.
Comments for offer & related information
The rights issue is 100 percent secured through subscription commitments, guarantee commitments and intent statements. Subscription commitments have been provided by the Company's major shareholders, including Daniel Johnsson, FV Group, Ancoria, Handelsbanken Fonder, Fourth AP Fonden, Third AP Fonden and Second AP Fonden, amounting to approximately 43 percent of the Rights Issue. In addition, participants in the Directed New Issue and additional investors have issued royalty-free guarantee commitments and declarations of intent, corresponding to approximately 57 percent of the Rights Issue.
People
Number of Employees
16 people
Nicholas Waters
CEO
Anders Vedin
Chairman of the board
Anders Vedin
Board member
Eva Lindgren
Board member
Hans-Peter Ostler
Board member
Rein Piir
Board member
Jacob Testor
Board member
Company Details
Sector
HEALTH CARE, TECHNOLOGY

Address
Arvid Wallgrens Backe 20
Zip code
413 46
City/district
Göteborg
Country
Sweden (SE)
Registration number
556931-4692
LEI code
549300JAT34LHEI0DH60
First trade date
28 Feb 2017
Registration date
16 May 2013
Short name
IRLAB Therapeutics A

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date